Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 May;26(3):148-54.
doi: 10.1002/jcla.21502.

Identification of novel low molecular weight serum peptidome biomarkers for non-small cell lung cancer (NSCLC)

Juan Yang  1 , Yong-Chun Song, Tu-Sheng Song, Xiao-Yan Hu, You-Min Guo, Zong-Fang Li, Cheng-Xue Dang, Chen Huang
Affiliations

Identification of novel low molecular weight serum peptidome biomarkers for non-small cell lung cancer (NSCLC)

Juan Yang et al. J Clin Lab Anal. 2012 May.

Abstract

Aim: To identify discriminating protein patterns in serum samples among non-small cell lung cancer (NSCLC), chronic obstructive pulmonary disease (COPD), pneumonia, and healthy controls. To discover specific low molecular weight (LMW) serum peptidome biomarkers and establish a diagnostic pattern for NSCLCby using proteomic technology.

Methods: We used magnetic bead-based separation followed by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) to identify patients with NSCLC, COPD, and pneumonia. A total of 154 serum samples were analyzed in this study, among which there were 60 serum samples from NSCLC patients, 30 from patients with other lung-related diseases (16 pneumonia patients and 14 patients with COPD) as disease controls, and 64 from healthy volunteers as healthy control. The mass spectra, analyzed using ClinProTools software, distinguished between cancer patients and healthy individuals based on GA algorithm model.

Results: In this study, we generated numerous discriminating m/z peaks as well as disease-specific discrimination peaks. A set of five potential biomarkers (m/z: 7,763.24, 1,012.61, 4,153.16, 1,450.55, and 2,878.89) could be used as the diagnostic biomarkers to distinguish NSCLCpatients from healthy controls. In the training set, patients with NSCLC could be identified with sensitivity of 97.5% and specificity of 98.8%. Similar results were obtained in the testing set, showing 80.7% sensitivity and 91.2% specificity.

Conclusion: Our study demonstrated that a combined application of magnetic beads with MALDI-TOF MS technique was suitable for identification of serum biomarkers for NSCLC.

PubMed Disclaimer

Conflict of interest statement

The authors confirm that they have no financial or personal relationships that cause a conflict of interest regarding the work in the manuscript.

Figures

Figure 1
Figure 1
Mass spectra (1,000–10,000 Da) obtained from NSCLC, pneumonia and COPD patients, and healthy controls. m/z, mass‐to‐charge ratio.
Figure 2
Figure 2
Comparison of the average expression levels of 20 NSCLC‐specific m/z peaks (P < 0.001) between NSCLCs and controls.
Figure 3
Figure 3
Comparison of the average expression levels of five pneumonia‐specific m/z peaks (P < 0.001) between pneumonias and controls.
Figure 4
Figure 4
Comparison of the average expression levels of 14 COPD‐specific m/z peaks (P < 0.001) between COPDs and controls.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Goldstraw P, Crowley J, Chansky K, et al. International Association for the Study of Lung Cancer International Staging Committee; Participating institutions. The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:706–714. - PubMed
    1. Vivian B, Stefan H, Benjamin N, et al. Relevance of circulating biomarkersfor the therapy monitoring and follow‐up investigations in patients with non‐small cell lung cancer. Cancer Biomark 2010;6:191–196. - PubMed
    1. Patz EF, Campa MJ, Gottlin EB, et al. Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol 2007;25:5578–5583. - PubMed
    1. Tarro G, Perna A, Esposito C. Early diagnosis of lung cancer by detection of tumor liberated protein. J Cell Physiol 2005;203:1–5. - PubMed
    1. Sung HJ, Cho JY. Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep 2008;41:615–625. - PubMed

Publication types